{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:55:00Z","timestamp":1792018500250,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01176-w","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:22:59Z","timestamp":1768339379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Best practices in the application of parallelism for biomarker assay validation"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3749-1522","authenticated-orcid":false,"given":"Lindsay","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-8026","authenticated-orcid":false,"given":"John","family":"Allinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1720-3249","authenticated-orcid":false,"given":"Lakshmi","family":"Amaravadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-9138","authenticated-orcid":false,"given":"Robert","family":"Kernstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6929-9357","authenticated-orcid":false,"given":"Fabio","family":"Garofolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-5968","authenticated-orcid":false,"given":"Michele","family":"Gunsior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8421-8272","authenticated-orcid":false,"given":"Barry","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-8080","authenticated-orcid":false,"given":"Joel","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5619-0163","authenticated-orcid":false,"given":"Robert","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9144-1182","authenticated-orcid":false,"given":"Robert","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8050-8394","authenticated-orcid":false,"given":"Marc-Olivier","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9021-9114","authenticated-orcid":false,"given":"Honglue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3103-3150","authenticated-orcid":false,"given":"Lauren","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5421-8039","authenticated-orcid":false,"given":"Troy","family":"Voelker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"1176_CR1","doi-asserted-by":"crossref","unstructured":"Grotjan H.E. and B.A Keel. Data interpretation and quality control. Chapter 4; P 51\u201393 In \u201cImmunoassay\u201d edited by Diamandis E.P. and T.K. Christopolous, 1996, Academic Press Inc, San Diego, CA, USA.","DOI":"10.1016\/B978-012214730-2\/50005-4"},{"issue":"6","key":"1176_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S0731-7085(99)00244-7","volume":"21","author":"JW Findlay","year":"2000","unstructured":"Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21(6):1249\u201373.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"1176_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11095-005-9045-3","volume":"23","author":"JW Lee","year":"2006","unstructured":"Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res. 2006;23(2):312\u201328.","journal-title":"Pharm Res"},{"issue":"2","key":"1176_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4155\/bio.13.292","volume":"6","author":"LF Stevenson","year":"2014","unstructured":"Stevenson LF, Purushothama S. Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays. Bioanalysis. 2014;6(2):185\u201398.","journal-title":"Bioanalysis"},{"issue":"23","key":"1176_CR5","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.4155\/bio-2016-0245","volume":"8","author":"LE King","year":"2016","unstructured":"King LE. Parallelism experiments in biomarker ligand-binding assays to assess immunological similarity. Bioanalysis. 2016;8(23):2387\u201391.","journal-title":"Bioanalysis"},{"issue":"6","key":"1176_CR6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1208\/s12248-017-0146-9","volume":"19","author":"KJ Cowan","year":"2017","unstructured":"Cowan KJ, Amaravadi L, Cameron MJ, Fink D, Jani D, Kamat M, et al. Recommendations for selection and characterization of protein biomarker assay calibrator material. AAPS J. 2017;19(6):1550\u201363.","journal-title":"AAPS J"},{"issue":"14","key":"1176_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.4155\/bio-2017-0084","volume":"9","author":"J Tu","year":"2017","unstructured":"Tu J, Bennett P. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. Bioanalysis. 2017;9(14):1107\u201322.","journal-title":"Bioanalysis"},{"issue":"6","key":"1176_CR8","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1208\/s12248-016-9946-6","volume":"18","author":"ME Arnold","year":"2016","unstructured":"Arnold ME, Booth B, King L, Ray C. Workshop report: Crystal city VI-bioanalytical method validation for biomarkers. AAPS J. 2016;18(6):1366\u201372.","journal-title":"AAPS J"},{"issue":"23","key":"1176_CR9","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.4155\/bio-2016-4989","volume":"8","author":"S Richards","year":"2016","unstructured":"Richards S, Amaravadi L, Pillutla R, Birnboeck H, Torri A, Cowan KJ, et al. 2016 white paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (part 3 - LBA, biomarkers and immunogenicity). Bioanalysis. 2016;8(23):2475\u201396.","journal-title":"Bioanalysis"},{"key":"1176_CR10","unstructured":"Piccoli SP, Sauer JM, Ackermann B et al. Points to consider document: scientific and regulatory considerations for the analytical validation of assays used in the qualification of biomarkers in biological matrices. Biomarker Assay Collaborative Evidentiary Considerations Writing Group, Critical Path Institute. 2019. https:\/\/c-path.org\/wp-content\/uploads\/2019\/06\/evidconsid-whitepaper-analyticalsectionv2019.pdf"},{"issue":"3","key":"1176_CR11","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00707-z","volume":"24","author":"C Fernandez-Metzler","year":"2022","unstructured":"Fernandez-Metzler C, Ackermann B, Garofolo F, Arnold ME, DeSilva B, Gu H, et al. Biomarker assay validation by mass spectrometry. AAPS J. 2022;24(3):66.","journal-title":"AAPS J"},{"issue":"1","key":"1176_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1476-5381.1966.tb01876.x","volume":"28","author":"DJ Finney","year":"1966","unstructured":"Finney DJ, Schild HO. Parallel line assay with successive adjustment of doses. Br J Pharmacol Chemother. 1966;28(1):84\u201392.","journal-title":"Br J Pharmacol Chemother"},{"issue":"2","key":"1176_CR13","first-page":"E97","volume":"235","author":"A DeLean","year":"1978","unstructured":"DeLean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978;235(2):E97\u2013102.","journal-title":"Am J Physiol"},{"issue":"8","key":"1176_CR14","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/clinchem\/31.8.1264","volume":"31","author":"RA Dudley","year":"1985","unstructured":"Dudley RA, Edwards P, Ekins RP, Finney DJ, McKenzie IG, Raab GM, et al. Guidelines for immunoassay data processing. Clin Chem. 1985;31(8):1264\u201371.","journal-title":"Clin Chem"},{"key":"1176_CR15","unstructured":"United States Pharmacopeia (2023).\u00a0General Chapter, \u23291034\u232a Analysis of Biological Assays. USP-NF. Rockville, MD: United States Pharmacopeia."},{"issue":"4","key":"1176_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/10543406.2020.1730875","volume":"30","author":"P Faya","year":"2020","unstructured":"Faya P, Rauk AP, Griffiths KL, Parekh B. A curve similarity approach to parallelism testing in bioassay. J Biopharm Stat. 2020;30(4):721\u201333.","journal-title":"J Biopharm Stat"},{"issue":"3","key":"1176_CR17","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00708-y","volume":"24","author":"A Hays","year":"2022","unstructured":"Hays A, Amaravadi L, Fernandez-Metzler C, King L, Mathews J, Ni Y, et al. Is incurred sample reanalysis (ISR) applicable in biomarker assays? AAPS J. 2022;24(3):65.","journal-title":"AAPS J"},{"issue":"19","key":"1176_CR18","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.4155\/bio.12.200","volume":"4","author":"BR Jones","year":"2012","unstructured":"Jones BR, Schultz GA, Eckstein JA, Ackermann BL. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis. 2012;4(19):2343\u201356.","journal-title":"Bioanalysis"},{"issue":"18","key":"1176_CR19","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.4155\/bio-2021-0173","volume":"13","author":"Y Ohtsu","year":"2021","unstructured":"Ohtsu Y, Tanaka S, Igarashi H, Kakehi M, Mori T, Nakamura T, et al. Analytical method validation for biomarkers as a drug development tool: points to consider. Bioanalysis. 2021;13(18):1379\u201389.","journal-title":"Bioanalysis"},{"key":"1176_CR20","unstructured":"Guidance on Bioanalytical Method Validation for Biomarkers. Guidance for Industry. 2025. Bioanalytical Method Validation for Biomarkers Guidance. https:\/\/www.hhs.gov\/guidance\/sites\/default\/files\/hhs-guidance-documents\/FDA\/biomarkers-guidance-level-2.pdf?mptk=12ca3c4bf78c6ccdd6f5770d6041e079869e76e7a93fcb93d3c570dd96e5f9ee57bbcfd331aa786762c48a6d5e8eaf79_87363bae8a7."},{"key":"1176_CR21","unstructured":"Guidance for Industry, Bioanalytical Method Validation. US FDA, 2018. https:\/\/ www. fda. gov\/ files\/ drugs\/ published\/ Bioanalytical- Method- Validation- Guidance- for- Industry. Bioanalytical Method Validation Guidance for Industry"},{"key":"1176_CR22","unstructured":"M10 Bioanalytical method validation and study sample analysis. ICH Harmonised Guideline: Geneva, Switzerland. 2022. https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524"},{"issue":"3","key":"1176_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1208\/s12248-012-9360-7","volume":"14","author":"VC Cullen","year":"2012","unstructured":"Cullen VC, Fredenburg RA, Evans C, Conliffe PR, Solomon ME. Development and advanced validation of an optimized method for the quantitation of Abeta42 in human cerebrospinal fluid. AAPS J. 2012;14(3):510\u20138.","journal-title":"AAPS J"},{"issue":"1","key":"1176_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1208\/s12248-011-9251-3","volume":"13","author":"JW Lee","year":"2011","unstructured":"Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, et al. Bioanalytical approaches to quantify \u201ctotal\u201d and \u201cfree\u201d therapeutic antibodies and their targets: technical challenges and PK\/PD applications over the course of drug development. AAPS J. 2011;13(1):99\u2013110.","journal-title":"AAPS J"},{"issue":"1","key":"1176_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-014-9685-5","volume":"17","author":"R Jenkins","year":"2015","unstructured":"Jenkins R, Duggan JX, Aubry AF, Zeng J, Lee JW, Cojocaru L, et al. Recommendations for validation of LC-MS\/MS bioanalytical methods for protein biotherapeutics. AAPS J. 2015;17(1):1\u201316.","journal-title":"AAPS J"},{"issue":"2","key":"1176_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/clinchem\/hvz022","volume":"66","author":"H Neubert","year":"2020","unstructured":"Neubert H, Shuford CM, Olah TV, Garofolo F, Schultz GA, Jones BR, et al. Protein biomarker quantification by immunoaffinity liquid chromatography-tandem mass spectrometry: current state and future vision. Clin Chem. 2020;66(2):282\u2013301.","journal-title":"Clin Chem"},{"issue":"14","key":"1176_CR27","doi-asserted-by":"publisher","first-page":"985","DOI":"10.4155\/bio-2022-0058","volume":"14","author":"K Agrawal","year":"2022","unstructured":"Agrawal K, Shi Y, Del Rosario AM, Jian W. Method development workflow for quantifying protein biomarkers by hybrid LC-MS\/MS. Bioanalysis. 2022;14(14):985\u20131004.","journal-title":"Bioanalysis"},{"issue":"4","key":"1176_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4155\/bio-2020-0324","volume":"13","author":"H Neubert","year":"2021","unstructured":"Neubert H, Alley SC, Lee A, Jian W, Buonarati M, Edmison A, et al. 2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome (Part 1 - Recommendations on Industry\/Regulators Consensus on BMV of Biotherapeutics by LCMS, Advanced Application in Hybrid Assays, Regulatory Challenges in Mass Spectrometry, Innovation in Small Molecules, Peptides and Oligos). Bioanalysis. 2021;13(4):203\u201338.","journal-title":"Bioanalysis"},{"issue":"1","key":"1176_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-015-9820-y","volume":"18","author":"D Jani","year":"2016","unstructured":"Jani D, Allinson J, Berisha F, Cowan KJ, Devanarayan V, Gleason C, et al. Recommendations for use and fit-for-purpose validation of biomarker multiplex ligand binding assays in drug development. AAPS J. 2016;18(1):1\u201314.","journal-title":"AAPS J"},{"issue":"2","key":"1176_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4155\/bio.14.274","volume":"7","author":"MU Khan","year":"2015","unstructured":"Khan MU, Bowsher RR, Cameron M, Devanarayan V, Keller S, King L, et al. Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. Bioanalysis. 2015;7(2):229\u201342.","journal-title":"Bioanalysis"},{"issue":"2","key":"1176_CR31","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-0412-0","volume":"22","author":"JA Mathews","year":"2020","unstructured":"Mathews JA, Ni YG, Wang C, Peterson JE, Ray C, Zhao X, et al. Considerations for soluble protein biomarker blood sample matrix selection. AAPS J. 2020;22(2):38.","journal-title":"AAPS J"},{"key":"1176_CR32","doi-asserted-by":"crossref","unstructured":"Welink J, Xu Y, Yang E, Wilson A, Henderson N. Luo L et al. White Paper on Recent Issues in Bioanalysis: \u2019A global bioanalytical community perspective on last decade of incurred samples reanalysis (ISR)\u2019 (Part 1 \u2013 small molecule regulated bioanalysis, small molecule biomarkers, peptides & oligonucleotide bioanalysis). Bioanalysis (2018) 10(22), 1781\u20131801.","DOI":"10.4155\/bio-2018-0268"},{"issue":"5","key":"1176_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4155\/bio-2021-0255","volume":"14","author":"XI Qiu","year":"2022","unstructured":"Qiu XI, Savaryn JP, Ruterbories KJ, Ji QC, Jenkins G. Comparison of three parallelism assessment methods of biomarker quantification by LC-MS\/MS: a case study of the bioanalysis of creatinine in human urine samples. Bioanalysis. 2022;14(5):279\u201387.","journal-title":"Bioanalysis"},{"key":"1176_CR34","doi-asserted-by":"crossref","unstructured":"Yang E, Welink J, Cape S, Woolf E, Sydor J, et al.\u00a02016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV) (Part 1 \u2013 Small Molecules, Peptides and Small Molecule Biomarkers by LCMS) - Bioanalysis (2016) 8(22), 2363\u20132378","DOI":"10.4155\/bio-2016-4992"},{"issue":"1","key":"1176_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56693-4","volume":"9","author":"N Sarigul","year":"2019","unstructured":"Sarigul N, Korkmaz F, Kurultak I. A new artificial urine protocol to better imitate human urine. Sci Rep. 2019;9(1):20159.","journal-title":"Sci Rep"},{"issue":"7","key":"1176_CR36","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/rcm.7509","volume":"30","author":"S Hooshfar","year":"2016","unstructured":"Hooshfar S, Basiri B, Bartlett MG. Development of a surrogate matrix for cerebral spinal fluid for liquid chromatography\/mass spectrometry based analytical methods. Rapid Commun Mass Spectrom. 2016;30(7):854\u20138.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"23","key":"1176_CR37","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.4155\/bio-2019-0270","volume":"11","author":"B Booth","year":"2019","unstructured":"Booth B, Stevenson L, Pillutla R, Buonarati M, Beaver C, Fraier D, et al. White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (Part 2 - Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies\u2019 Input on Bioanalysis, Biomarkers and Immunogenicity). Bioanalysis. 2019;11(23):2099\u2013132.","journal-title":"Bioanalysis"},{"issue":"4","key":"1176_CR38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1208\/s12248-015-9756-2","volume":"17","author":"JF Marcelletti","year":"2015","unstructured":"Marcelletti JF, Evans CL, Saxena M, Lopez AE. Calculations for adjusting endogenous biomarker levels during analytical recovery assessments for ligand-binding assay bioanalytical method validation. AAPS J. 2015;17(4):939\u201347.","journal-title":"AAPS J"},{"key":"1176_CR39","doi-asserted-by":"crossref","unstructured":"van Waalwijk van Doorn LJC, Kulic L, Koel-Simmelink MJA, Kuiperij HB, Versleijen AAM, Struyfs H, et al. Multicenter Analytical Validation of Abeta 40 Immunoassays. Front Neurol. 2017; 8:310.","DOI":"10.3389\/fneur.2017.00310"},{"issue":"2","key":"1176_CR40","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3390\/app14020602","volume":"14","author":"PA Partial","year":"2024","unstructured":"Partial PA, Plots P. Appl Sci. 2024;14(2):602\u201321.","journal-title":"Appl Sci"},{"key":"1176_CR41","unstructured":"Bortolotto E, Rousseau R, Teodorescu B, Wielant A and G. Debauve Assessing Similarity with Parallel-Line and Parallel-Curve Models: Implementing the USP Development\/Validation Approach to a Relative Potency Assay. http:\/\/www.bioprocessintl.com\/upstream-processing\/assays\/assessing-similarity-with-parallel-line-and-parallel-curve-models-implementing-the-usp-developmentvalidation-approach-to-a-relative-potency-assay"},{"issue":"3","key":"1176_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1081\/BIP-200056532","volume":"15","author":"PG Gottschalk","year":"2005","unstructured":"Gottschalk PG, Dunn JR. Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data. J Biopharm Stat. 2005;15(3):437\u201363.","journal-title":"J Biopharm Stat"},{"issue":"15","key":"1176_CR43","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.4155\/bio.12.164","volume":"4","author":"P Timmerman","year":"2012","unstructured":"Timmerman P, Herling C, Stoellner D, Jaitner B, Pihl S, Elsby K, et al. European bioanalysis forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development. Bioanalysis. 2012;4(15):1883\u201394.","journal-title":"Bioanalysis"},{"key":"1176_CR44","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jpba.2011.03.033","volume":"55","author":"M-A Valentina","year":"2011","unstructured":"Valentina M-A, Mab S, Zhaob A, Legaya F, Avrameasa A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal. 2011;55:869\u201377.","journal-title":"J Pharm Biomed Anal"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01176-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01176-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01176-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:20:35Z","timestamp":1770826835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01176-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01176-w","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article reflects the views of the authors and should not be construed to represent their organizations\u2019 views or policies. This paper was researched and written by the Parallelism sub-team of the Biomarker and Precision Medicine Community of AAPS and may not reflect the position of all AAPS members.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"There are no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"50"}}